Jump to main content
Jump to site search


Augmenting T-cell responses to tumors by in situ nanomanufacturing

Author affiliations

Abstract

Recent innovations in immunoregulatory treatments have demonstrated both the impressive potential and vital role of T cells in fighting cancer. These treatments come at a cost, with systemic side effects including life-threatening autoimmunity and immune dysregulation the norm. Here, we developed an approach to locally synthesize immune therapies and in this way, avoid systemic toxicity. Rather than just encapsulating cytokines, we endowed our nanoparticles with transcriptional and translational machinery to make cytokines locally, in situ, and on demand (activated by light). We demonstrated the capabilities of these particles in vitro and in vivo, in a mouse model of melanoma, and showed that tumor-infiltrating T cells were more highly activated in the context of these “microfactory” particles that make the synthetic cytokine.

Graphical abstract: Augmenting T-cell responses to tumors by in situ nanomanufacturing

Back to tab navigation

Supplementary files

Article information


Submitted
06 May 2020
Accepted
15 Sep 2020
First published
29 Sep 2020

Mater. Horiz., 2020, Advance Article
Article type
Communication

Augmenting T-cell responses to tumors by in situ nanomanufacturing

M. M. Hasani-Sadrabadi, F. S. Majedi, M. L. Miller, T. J. Thauland, Louis-S. Bouchard, S. Li and M. J. Butte, Mater. Horiz., 2020, Advance Article , DOI: 10.1039/D0MH00755B

Social activity

Search articles by author

Spotlight

Advertisements